System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

François Schiele is an expert in Cardiology at Centre Hospitalier Universitaire de Besançon (France). As of October 2026, ScienceLeadR ranks François Schiele in the top 1% of experts worldwide for Myocardial Ischemia. François Schiele has authored 615 publications, the most recent in 2026, and is an investigator in 44 clinical trials, 5 of them ongoing. SLR score: 2,267 (community average: 125). How the SLR is computed.

LeadR Profile

François Schiele Centre Hospitalier Universitaire de Besançon France
2 267 ScienceLeadR Reputation 2267

Unlock

Register Login
Network Map

Cardiology

Subspecialties: Public Health - Biostatistics - Endocrinology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1987 - 2026
Source: PubMed

Hôpital Saint-Jacques (France, Besançon)

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 615

Citations

Citations: 49 179 1st author: 98 Last author: 73 Unique author: 14

Main journals

Eur Heart J 85
J Am Coll Cardiol 66
Circulation 43
Archives of Cardiovascular Diseases Supplements 36
N Engl J Med 24

Best Journals

N Engl J Med 24
Eur Heart J 11
Circulation 10

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Efficacy and Safety of Semaglutide According to Frailty Status: A Post Hoc Analysis of the SELECT Randomized Clinical Trial.
PMID 42747817 — glucagon-like peptide 1, quality of life, safety, cardiovascular diseases, frailty, semaglutide		JAMA Cardiol20261
Unsupervised clustering identifies distinct phenotypes in acute myocardial infarction: insights from the FAST-MI 2015 registry.
PMID 42689178 — registries, mortality, myocardial infarction, phenotype, classification, acute coronary syndrome, cluster analysis, precision medicine, prognosis		Front Artif Intell20260
LDL Cholesterol Lowering With Evolocumab Before Percutaneous Coronary Intervention for Acute Myocardial Infarction: The AMUNDSEN Randomized Clinical Trial.
PMID 42666092 — cholesterol, ldl, myocardial infarction, percutaneous coronary intervention, cholesterol, odds ratio, therapeutics		JAMA Top journal20262
Early lipid-lowering strategies after acute coronary syndrome: strike strong or start smart?
PMID 42667313 — cardiovascular diseases, acute coronary syndrome, secondary prevention, strikes, employee		Eur J Prev Cardiol20260
Perspectives on caregiver-reported outcomes in cardiovascular diseases today and in future healthcare services: a statement of Association of Cardiovascular Nursing & Allied Professions (ACNAP), Association for Acute CardioVascular Care (ACVC), the Heart Failure Association (HFA), ESC Council on Stroke, and Global Heart Hub, the International Alliance of Heart Patient Organisations.
PMID 41914819 — stroke, heart failure, heart, caregivers, nursing, cardiovascular diseases, cardiovascular nursing, occupations		Eur J Cardiovasc Nurs20260

Clinical Studies 44

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

Phase 3 22
N/A 15
Phase 4 7

By status:

Completed 33
Active not recruiting 4
Recruiting 4
Unknown 2
Terminated 1

By type:

Interventional 35
Observational 9

By Monocentric/Multicentric:

monocentric 17
multicentric2to4 1
multicentric5to9 1
multicentricup10 25

Main Topics

Cohort/Consortium Investigators 3

Ongoing Clinical Trials

5 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
DAPAgliflozine to attenuate cardiac RemOdeling afTEr aCuTe myOcardial infarction
2024-511882-13-01 — myocardial infarction, heart failure, echocardiography, therapeutics		Phase 3Active not recruiting2024
Long term safety and tolerability of inclisiran in participants with heterozygous familial hypercholesterolaemia or homozygous familial hypercholesterolaemia who have completed the adolescent ORION 16 or ORION 13 studies
2023-507278-41-00 — hyperlipoproteinemia type ii, safety, adolescent, hypercholesterolemia, homozygous familial hypercholesterolemia		Phase 3Active not recruiting2023
Sudden Cardiac Arrest Related to Sport in Young and Value of the Genetic Assessment a French Prospective Register
NCT06642168 — death, sudden, heart diseases, heart arrest, toxicology, diagnosis, death, sudden, cardiac, exome, exome sequencing, athletes, mutation, sports, autopsy		N/ARecruiting2024
Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCI
NCT04951856 — injections, myocardial infarction, st elevation myocardial infarction, hydroxymethylglutaryl-coa reductase inhibitors, non-st elevated myocardial infarction, random allocation, injections, subcutaneous		Phase 4Active not recruiting2021
SCAD a Registry of Spontaneous Coronary Artery Dissection
NCT06601270 — registries, arteries, vascular diseases, coronary vessel anomalies, aortic dissection, dissection, coronary vessels		N/ARecruiting2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS